Abstract

TARGETED PROTEINS FOR RECENT AND EMERGING DIABETES MELLITUS RESEARCH

Kuldeep Singh Patel*, Jagdish Chandra Rathi, Vivek Jain and Neeripama Dhamin

Abstract

Diabetes mellitus (DM) is a major degenerative disease in the world today. Several epidemiological and clinical studies indicate a direct relationship between hyperglycemia and long-term complications such as retinopathy, nephropathy, neuropathy and angiopathy, etc. India has today become the diabetic capital of the world with over 20 million diabetics and this number is set to increase to 57 million by 2025. It is ranked seventh among the leading causes of death and is considered third when its fatal complications are taken into account. DM is a multifactorial disease which is characterized by hyperglycemia, lipoprotein abnormalities, raised basal metabolic rate, defect in reactive oxygen species scavenging enzymes and high oxidative stress-induced damage to pancreatic beta cells. Several drugs are presently available to reduce hyperglycemia in diabetes mellitus. These drugs have side effects and thus searching for a new class of compounds is essential to overcome this problems. Nevertheless, there is continuous search for alternative drugs; management of diabetes without any side effects is still a challenge to the medicinal chemist. Therefore, it is prudent to look for options in novel drugs for diabetes. In this review article, we will review the role of future new chemicals entities able to target the metabolic disorder. Some of these new anti-diabetic treatment strategies may in the future not only control symptoms and modify the natural course of diabetes, but also potentially prevent or cure the disease.

Keywords: Diabetes Mellitus, Metabolic Disorder, Antidiabetics, DPP-IV Inhibitors.